Description

Lixisenatide acetate is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Metabolism-sugar/lipid metabolism–C215H347N61O65S.6C2H4O2—-[1]Ahrén B et al. Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis. Diabetes Ther. 2016 Jun 18.|[2]Lorenz M, et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes–relationship to postprandial glycemia. Regul Pept. 2013 Aug 10;185:1-8.–1997361-87-1–5218.79–99.65–O=C([C@@H](N)CC1=CNC=N1)NCC(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(NCC(N2[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N3[C@H](C(N4[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N)=O)CCCCN)=O)CCCCN)=O)CCCCN)=O)CCCCN)=O)CCCCN)=O)CCCCN)=O)CO)=O)CCC4)=O)CCC3)=O)C)=O)=O)CO)=O)CO)=O)CCC2)=O)=O)=O)CC(N)=O)=O)CCCCN)=O)CC(C)C)=O)CC5=CNC6=CC=CC=C56)=O)CCC(O)=O)=O)[C@H](CC)C)=O)CC7=CC=CC=C7)=O)CC(C)C)=O)CCCNC(N)=N)=O)C(C)C)=O)C)=O)CCC(O)=O)=O)CCC(O)=O)=O)CCC(O)=O)=O)CCSC)=O)CCC(N)=O)=O)CCCCN)=O)CO)=O)CC(C)C)=O)CC(O)=O)=O)CO)=O)[C@@H](C)O)=O)CC8=CC=CC=C8)=O)[C@@H](C)O)=O)=O)CCC(O)=O)=O.CC(O)=O–Metabolic Disease–H2O : 50 mg/mL (ultrasonic)–GCGR—-GPCR/G Protein–Peptides